8-K current report · filed Nov 5, 2026

Sana Biotechnology, Inc. (SANA) 8-K Current Report: November 5, 2026

Item 2.02Item EX-99.1SANA overview

Short answer

Sana Biotechnology, Inc. (SANA) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for quarter ended September 30, 2026.

Sana Biotechnology, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Detailed results and management commentary contained in Exhibit 99.1, the accompanying press release

Item EX-99.1 · Exhibit EX-99.1

  • Cash $121.7M at September 30, 2026, with runway into mid-2027, but nine-month non-GAAP operating cash burn reached $103.4M
  • SC451 IND and Phase 1/2 trial targeted as early as 2026, creating a near-term clinical catalyst in type 1 diabetes
  • SG293 clinical study in non-Hodgkin lymphoma targeted for 1Q 2027, with first-in-human data potentially in the first half of 2027
  • UP421 showed 14-month beta-cell survival and function without immunosuppression, supporting Sana’s HIP platform while remaining single-patient evidence
  • Q3 GAAP net income $20.4M reflected $63.4M of non-cash liability valuation gains, while non-GAAP net loss was $43.0M###

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Sana Biotechnology, Inc. 8-K filings

Get the next SANA 8-K as it lands

Follow SANA for push alerts, or ask the research agent what this filing means.